Reinsurance Group Of America RGA

NYSE RGA

$250.26 -3.01 (-1.19%)

As of: Sep 8, 2026 · 12:26 PM EDT

Key Stats

Market Cap16.26 Bn

P/E10.73

P/S0.63

Div. Yield0.02

Total Debt (Qtr)5.71 Bn

Revenue Growth (1y) (Qtr)18.54

Add ratio to table…

About

Reinsurance Group of America, Incorporated is a leading global provider of traditional life and health and asset intensive reinsurance solutions. The company offers reinsurance for mortality morbidity lapse and investment risks associated with life health disability long term care critical illness annuities and other insurance products. The company generates revenue primarily from premiums earned on traditional life and health reinsurance contracts and from asset intensive…

The company generates revenue primarily from premiums earned on traditional life and health reinsurance contracts and from asset intensive reinsurance agreements that include annuities variable products and stable value offerings. Additional revenue comes from financial solutions such as longevity reinsurance pension risk transfer transactions and capital solutions that provide regulatory surplus support to clients. Investment income from unallocated invested assets and service fees also contribute to earnings.

The company operates through the following segments: Traditional, Financial Solutions, and Corporate and Other.

Traditional: This segment provides individual and group life and health reinsurance including disability long term care and critical illness coverage on facultative or automatic treaty basis using yearly renewable term coinsurance and modified coinsurance structures.
Financial Solutions: This segment encompasses asset intensive reinsurance longevity reinsurance stable value products pension risk transfer and capital solutions that help clients manage investment risk longevity risk and regulatory capital requirements.
Corporate and Other: This segment consists of investment income from unallocated invested assets service fees and results from previously issued funding agreement backed notes along with offsets to capital charges and other corporate overhead.

The company holds a leading position in the global reinsurance market competing with firms such as Munich Re Swiss Re Hannover Re and SCOR. Its competitive advantages stem from strong financial strength ratings including A. M. Best A plus, S&P double A minus, and Moody's A one, a diversified product line across traditional and financial solutions, and a broad international footprint that enables it to serve clients in multiple regions.

The company serves primarily large life insurance companies worldwide. In 2025 the five largest clients generated approximately $3.9 billion or 21% of gross premiums and other revenues while 36 other clients each contributed $100 million or more representing about 46% of the total. No single client accounted for 10% or more of revenue.

Investment Thesis

▲ Bull case

Reinsurance Group of America, Incorporated is positioned to capitalize on sustained demand for complex risk solutions in Asia and Europe, where clients are actively seeking partners capable of managing both biometric and asset risks amid evolving regulatory frameworks and capital constraints. In Japan and Korea, insurers are adapting to new capital requirements under local solvency regimes, creating opportunities for RGA to deploy its unique combination of asset management and biometric expertise in coinsurance and in-force transactions that were highlighted in the earnings call as delivering attractive risk-adjusted returns. The company’s ability to structure deals that unlock incremental capital for cedants—such as the EMEA longevity transaction described by management—provides a self-reinforcing flywheel: as partners gain balance sheet relief, they are more likely to return for additional transactions, deepening relationships and expanding RGA’s wallet share. This dynamic is particularly potent in markets where local reinsurers lack the scale or expertise to handle long-duration, complex liabilities, giving RGA a structural advantage that is not fully reflected in current valuation multiples. Furthermore, the company’s disciplined approach to walking away from suboptimal deals ensures that deployed capital continues to generate returns above its 8% to 10% EPS growth threshold, supporting sustainable earnings expansion without compromising credit quality or increasing risk concentration.
The ongoing tailwinds from GLP-1 adoption and improving mortality trends in the U.S. individual life segment represent a material, underappreciated source of future earnings power that is not yet fully priced into the stock. While management has not formally revised mortality assumptions, they acknowledged observing positive momentum from GLP-1s—including expanded Medicare and Medicaid coverage and the approval of lower-cost oral formulations—which, when combined with the already-favorable underlying claims experience observed since 2023, suggests a higher probability of mortality improvement than currently assumed in reserving. The $343 million of cumulative economic mortality favorability since 2023, with approximately $20 million per year expected to flow through earnings over the long term, represents a significant reservoir of future profit emergence that could substantially boost run-rate profitability if trends persist or accelerate. Given that the stock currently trades at a discount to peers based on near-term earnings multiples, any upward revision to mortality assumptions—or even the recognition of existing favorable experience as it releases from reserves—could trigger a meaningful rerating, especially as investors begin to focus more on the quality and sustainability of earnings rather than just headline growth.
Reinsurance Group of America, Incorporated’s capital deployment strategy is evolving to exploit structural inefficiencies in the global reinsurance market, particularly through its proprietary sidecar platforms like Ruby Re, which allow the company to access third-party capital while retaining economic exposure to high-quality, complex liabilities. The flexibility to deploy capital via structures that generate fee income, reduce net risk exposure, and enhance return on equity—without requiring full balance sheet absorption—provides a leveraged pathway to growth that is underleveraged in current investor models. Management emphasized that third-party capital remains a core element of their strategy, enhancing flexibility to fund growth and return capital to shareholders while generating incremental fee income. As primary insurers and other reinsurers increasingly turn to captives and sidecars for capital efficiency—cited by analysts on the call as a growing trend—RGA’s early mover advantage in structuring such vehicles for complex liabilities like long-term care and universal life with secondary gaps positions it to capture a disproportionate share of this expanding market. This ability to monetize expertise through fee-based models, rather than relying solely on underwriting spread, could significantly improve the durability and scalability of earnings over time, especially in environments where traditional treaty capacity is constrained by capital or regulatory limits.

Reinsurance Group of America, Incorporated is positioned to capitalize on sustained demand for complex risk solutions in Asia and Europe, where clients are actively seeking partners capable of managing both biometric and asset risks amid evolving regulatory frameworks and capital constraints. In Japan and Korea, insurers are adapting to new capital requirements under local solvency regimes, creating opportunities for RGA to deploy its unique combination of asset management and biometric expertise in coinsurance and in-force transactions that were highlighted in the earnings call as delivering attractive risk-adjusted returns. The company’s ability to structure deals that unlock incremental capital for cedants—such as the EMEA longevity transaction described by management—provides a self-reinforcing flywheel: as partners gain balance sheet relief, they are more likely to return for additional transactions, deepening relationships and expanding RGA’s wallet share. This dynamic is particularly potent in markets where local reinsurers lack the scale or expertise to handle long-duration, complex liabilities, giving RGA a structural advantage that is not fully reflected in current valuation multiples. Furthermore, the company’s disciplined approach to walking away from suboptimal deals ensures that deployed capital continues to generate returns above its 8% to 10% EPS growth threshold, supporting sustainable earnings expansion without compromising credit quality or increasing risk concentration.
The ongoing tailwinds from GLP-1 adoption and improving mortality trends in the U.S. individual life segment represent a material, underappreciated source of future earnings power that is not yet fully priced into the stock. While management has not formally revised mortality assumptions, they acknowledged observing positive momentum from GLP-1s—including expanded Medicare and Medicaid coverage and the approval of lower-cost oral formulations—which, when combined with the already-favorable underlying claims experience observed since 2023, suggests a higher probability of mortality improvement than currently assumed in reserving. The $343 million of cumulative economic mortality favorability since 2023, with approximately $20 million per year expected to flow through earnings over the long term, represents a significant reservoir of future profit emergence that could substantially boost run-rate profitability if trends persist or accelerate. Given that the stock currently trades at a discount to peers based on near-term earnings multiples, any upward revision to mortality assumptions—or even the recognition of existing favorable experience as it releases from reserves—could trigger a meaningful rerating, especially as investors begin to focus more on the quality and sustainability of earnings rather than just headline growth.
Reinsurance Group of America, Incorporated’s capital deployment strategy is evolving to exploit structural inefficiencies in the global reinsurance market, particularly through its proprietary sidecar platforms like Ruby Re, which allow the company to access third-party capital while retaining economic exposure to high-quality, complex liabilities. The flexibility to deploy capital via structures that generate fee income, reduce net risk exposure, and enhance return on equity—without requiring full balance sheet absorption—provides a leveraged pathway to growth that is underleveraged in current investor models. Management emphasized that third-party capital remains a core element of their strategy, enhancing flexibility to fund growth and return capital to shareholders while generating incremental fee income. As primary insurers and other reinsurers increasingly turn to captives and sidecars for capital efficiency—cited by analysts on the call as a growing trend—RGA’s early mover advantage in structuring such vehicles for complex liabilities like long-term care and universal life with secondary gaps positions it to capture a disproportionate share of this expanding market. This ability to monetize expertise through fee-based models, rather than relying solely on underwriting spread, could significantly improve the durability and scalability of earnings over time, especially in environments where traditional treaty capacity is constrained by capital or regulatory limits.

▼ Bear case

Reinsurance Group of America, Incorporated faces mounting pressure from the accelerating trend of primary insurers establishing internal reinsurance captives and sidecars, which could erode its traditional treaty business by capturing the most capital-efficient, vanilla asset-intensive transactions that historically contributed to stable, predictable earnings. During the Q&A, analysts explicitly noted the rise of U.S. primary insurers setting up internal captives and third-party writing capabilities, some modeled after structures like Ruby Re, to generate capital efficiencies—a trend management acknowledged but downplayed by asserting their focus remains on complex biometric-asset risks. However, this dismissal overlooks the risk that as cedants gain greater capability to retain or reinsure simpler risks internally, the pool of available external reinsurance opportunities may shrink, particularly for the mid-sized, less complex treaties that form the foundation of RGA’s traditional business in North America and Europe. If this trend accelerates, RGA could be forced to compete more intensely for a dwindling pool of complex transactions, potentially driving down pricing or increasing the time and cost required to deploy capital, thereby pressuring margins and slowing the pace of profitable growth despite the company’s strong underlying franchises.
The company’s reliance on future earnings emergence from deferred mortality favorability introduces significant uncertainty into its earnings outlook, as the timing and magnitude of profit release from uncapped cohorts are highly sensitive to changes in mortality trends, regulatory accounting interpretations, and the volatility of actual experience versus expectations. While management cited $343 million of cumulative economic favorability since 2023 and noted an expected annual run-rate impact of approximately $20 million, they also acknowledged that much of this benefit remains deferred due to the structure of reserves under LDTI, with release occurring over the long tail of the business. Any reversal in mortality trends—whether due to unforeseen public health events, waning impact of GLP-1s, or increased morbidity from conditions like long COVID or obesity-related complications—could not only halt the release of deferred profits but trigger adverse reserve development, requiring additional capital buffers and weighing on profitability. Furthermore, the opacity around how and when this experience will surface in earnings makes it difficult for investors to model sustainable earnings power, increasing the risk of negative surprises if actual experience diverges from expectations, especially given the stock’s sensitivity to changes in long-term mortality assumptions.
Reinsurance Group of America, Incorporated’s capital deployment is increasingly exposed to execution risk in complex, structured transactions, where the company’s competitive advantage in combining biometric and asset expertise may be offset by longer timelines, higher legal and operational complexity, and greater dependence on counterparty willingness to innovate—factors that could slow the pace of capital deployment below levels needed to meet its 8% to 10% EPS growth target. Although management highlighted strong pipelines in Asia for in-force and flow deals involving both sides of the balance sheet, they also emphasized their willingness to walk away from transactions that do not meet risk-return thresholds, a discipline that, while prudent, risks creating periods of under-deployed capital if suitable opportunities are scarce or take longer to materialize. The acknowledgment that the timing and size of in-force management actions are difficult to predict, combined with the reliance on niche, high-touch structuring capabilities, suggests that earnings growth may become more lumpy and less predictable over time. In a rising interest rate environment where alternative uses of capital (such as share buybacks or debt reduction) offer predictable returns, the opportunity cost of delayed or lower-yielding deployments could weigh on investor confidence, particularly if the market begins to question whether RGA’s differentiated model can scale efficiently enough to deliver consistent, compounding growth without relying on episodic, large transactions.

Reinsurance Group of America, Incorporated faces mounting pressure from the accelerating trend of primary insurers establishing internal reinsurance captives and sidecars, which could erode its traditional treaty business by capturing the most capital-efficient, vanilla asset-intensive transactions that historically contributed to stable, predictable earnings. During the Q&A, analysts explicitly noted the rise of U.S. primary insurers setting up internal captives and third-party writing capabilities, some modeled after structures like Ruby Re, to generate capital efficiencies—a trend management acknowledged but downplayed by asserting their focus remains on complex biometric-asset risks. However, this dismissal overlooks the risk that as cedants gain greater capability to retain or reinsure simpler risks internally, the pool of available external reinsurance opportunities may shrink, particularly for the mid-sized, less complex treaties that form the foundation of RGA’s traditional business in North America and Europe. If this trend accelerates, RGA could be forced to compete more intensely for a dwindling pool of complex transactions, potentially driving down pricing or increasing the time and cost required to deploy capital, thereby pressuring margins and slowing the pace of profitable growth despite the company’s strong underlying franchises.
The company’s reliance on future earnings emergence from deferred mortality favorability introduces significant uncertainty into its earnings outlook, as the timing and magnitude of profit release from uncapped cohorts are highly sensitive to changes in mortality trends, regulatory accounting interpretations, and the volatility of actual experience versus expectations. While management cited $343 million of cumulative economic favorability since 2023 and noted an expected annual run-rate impact of approximately $20 million, they also acknowledged that much of this benefit remains deferred due to the structure of reserves under LDTI, with release occurring over the long tail of the business. Any reversal in mortality trends—whether due to unforeseen public health events, waning impact of GLP-1s, or increased morbidity from conditions like long COVID or obesity-related complications—could not only halt the release of deferred profits but trigger adverse reserve development, requiring additional capital buffers and weighing on profitability. Furthermore, the opacity around how and when this experience will surface in earnings makes it difficult for investors to model sustainable earnings power, increasing the risk of negative surprises if actual experience diverges from expectations, especially given the stock’s sensitivity to changes in long-term mortality assumptions.
Reinsurance Group of America, Incorporated’s capital deployment is increasingly exposed to execution risk in complex, structured transactions, where the company’s competitive advantage in combining biometric and asset expertise may be offset by longer timelines, higher legal and operational complexity, and greater dependence on counterparty willingness to innovate—factors that could slow the pace of capital deployment below levels needed to meet its 8% to 10% EPS growth target. Although management highlighted strong pipelines in Asia for in-force and flow deals involving both sides of the balance sheet, they also emphasized their willingness to walk away from transactions that do not meet risk-return thresholds, a discipline that, while prudent, risks creating periods of under-deployed capital if suitable opportunities are scarce or take longer to materialize. The acknowledgment that the timing and size of in-force management actions are difficult to predict, combined with the reliance on niche, high-touch structuring capabilities, suggests that earnings growth may become more lumpy and less predictable over time. In a rising interest rate environment where alternative uses of capital (such as share buybacks or debt reduction) offer predictable returns, the opportunity cost of delayed or lower-yielding deployments could weigh on investor confidence, particularly if the market begins to question whether RGA’s differentiated model can scale efficiently enough to deliver consistent, compounding growth without relying on episodic, large transactions.

Geographical Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Reinsurance

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	RGA	Reinsurance Group Of America Inc	primary	16.26 Bn	10.73	0.63	5.71 Bn
2	EG	Everest Group, Ltd.	primary	14.52 Bn	7.59	0.87	2.35 Bn
3	RNR	Renaissancere Holdings Ltd	primary	13.50 Bn	5.20	1.21	2.33 Bn
4	SPNT	SiriusPoint Ltd	primary	2.86 Bn	5.78	0.88	0.68 Bn
5	GLRE	Greenlight Capital Re, Ltd.	primary	0.50 Bn	9.87	0.69	0.01 Bn
6	OXBR	OXBRIDGE RE HOLDINGS Ltd	primary	0.01 Bn	29.48	4.04	0.00 Bn
7	RY	Royal Bank Of Canada	secondary	295.88 Bn	18.03	5.76	126.20 Bn
8	TD	Toronto Dominion Bank	secondary	208.62 Bn	18.52	4.46	221.61 Bn

Reinsurance Group Of America RGA

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password